EN DE
Watch Beihai Gofar Marine Biological Industry Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Beihai Gofar Marine Biological Industry Co Ltd (600538) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Beihai Gofar Marine Biological Industry Co Ltd stock ¥0.56, price ¥4.17, that is 86.6% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials CN · ISIN CNE000001DD2

BG Beihai Gofar Marine Biological Industry Co Ltd logo Thin data Nov 5, 2026

Beihai Gofar Marine Biological Industry Co Ltd

600538 · SHG
Very expensive, weak quality

Our calculation puts a fair price 87% below what the stock costs today.

Low debt
Quality 46/100
Fair value ¥0.5600 · Strongly overvalued
Weak Growth (revenue 3y −10.6 %/yr in CNY)
Loss-making · -27.9% net margin (TTM)
Negative free cash flow
Trails peers (1/10)
Narrow moat 12/100
Thin data
⟳ Cyclical
Watch Beihai Gofar Marine Biological Industry Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥10.70 ¥2.95 Fair Value ¥0.5600 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range ¥2.95 – ¥10.70 · fair‑value band ¥0.3700 – ¥0.7000 · the ¥4.17 price screens above the ¥0.5600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.

Follow Beihai Gofar Marine Biological Industry Co in your weekly email

Every Wednesday you see whether Beihai Gofar Marine Biological Industry Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, distributes pharmaceutical products in China. It operates through Pharmaceutical Distribution; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments.

Show moreShow less

The company wholesales and retails pharmaceutical products through hospitals, clinics, other medical institutions, pharmacies, health centers, clinics, directly operated stores, general agents, distributors, and allocations.

It also provides pearl eye drops, pearl powder, and pearl layer powder under the Haibao brand; brand gastrointestinal granules, honeysuckle oral solution, and children's syrup under the Guofa brand; and traumatic injury medicated wine, and sea snake medicated wine under the Haima brand.

In addition, the company produces and sells forensic DNA testing equipment, reagents, and consumables; and provides technical services, including DNA testing services. Further, it engages in culture and arts activities; and provision of technical services.

The company was formerly known as Beihai Gofar Marine Biological Industry Co., Ltd. and changed its name to Beihai Gofar Chuanshan Biological Co., Ltd. in June 2021. Beihai Gofar Chuanshan Biological Co., Ltd. was incorporated in 1993 and is headquartered in Beihai, China.

Stock analysis

Beihai Gofar Marine Biological Industry Co Ltd (600538) currently trades at ¥4.17, while our model-based Fair Value estimate is ¥0.5600, 87% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: ¥0.3700 (bear) to ¥0.7000 (bull), the price of ¥4.17 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Basic Materials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Beihai Gofar Marine Biological Industry Co Ltd reported revenue of 328M CNY in FY2025 versus 425M CNY in FY2021, a compound −6.2%/yr. Reported net income was −87.6M CNY in FY2025.

Key figures

Market cap 2.2B CNY (≈ $327M) Small · P/S ratio 6.48 · EPS (TTM) ¥−0.1800 · Net margin −27.9% · Return on equity −12.5% · Return on assets (EBIT) −2.9% (5-year average) · Operating margin −3.3% · Revenue (TTM) 334M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 44% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at 4% fair-value upside, at −87%, 600538 screens richer than that median.

Fair Value models

Bear ¥0.3700 Fair Value ¥0.5600 Bull ¥0.7000
Price ¥4.17 · Downside -86.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) ¥0.3700 ¥0.5600 ¥0.7000 55
All 1 models by family
Asset-Based
NCAV (Graham) ¥0.3700 ¥0.5600 ¥0.7000 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 89
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 73
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 70
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 15/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−3.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
Start year 2020 (pandemic). Over 10 years: −4.2% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.3% (2020) → −7.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

600538 screens overvalued: fair value 87% below the price. Compare with Nutrien Ltd →

Compare Beihai Gofar Marine Biological Industry Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 162 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside −86.6% · Bottom 25%
Profitability
Return on assets −9.8% · Bottom 25%
Net margin (12 months) −27.9% · Bottom 25%
Operating margin (12 months) −3.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 2.4% · Below median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Agricultural Inputs median · lower = cheaper

P/B 3.18× · Priciest 25%
P/S (12 months) 6.54× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)12 · sector 17
PAST (return on equity)0 · sector 29
HEALTH (low debt)99 · sector 98
DIVIDEND (yield)0 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Nutrien Ltd NTR $71.48 $83.09 +16% vs 600538
Qinghai Salt Lake Industry Co 000792 ¥23.15 ¥26.81 +16% vs 600538
The Mosaic Company MOS $22.36 $25.77 +15% vs 600538
Yara International ASA YAR kr 401.00 kr 419.83 +5% vs 600538
Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 ¥36.68 ¥38.01 +4% vs 600538
ICL Group ICL $4.68 $4.84 +3% vs 600538
CF Industries Holdings CF $119.39 $114.88 −4% vs 600538
UPL Limited UPL ₹534.90 ₹478.29 −11% vs 600538
Yunnan Yuntianhua Co 600096 ¥26.22 ¥17.67 −33% vs 600538
Coromandel International Limited COROMANDEL ₹1,824 ₹1,129 −38% vs 600538

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beihai Gofar Marine Biological Industry Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Beihai Gofar Marine Biological Industry Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600538

Frequently asked questions

Is Beihai Gofar Marine Biological Industry Co Ltd (600538) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥0.5600 versus a price of ¥4.17, about 87% lower (overvalued).
What is the fair value of 600538?
Our model-based fair value for Beihai Gofar Marine Biological Industry Co Ltd is ¥0.5600 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥4.17.
What is the quality score of 600538?
Beihai Gofar Marine Biological Industry Co Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beihai Gofar Marine Biological Industry Co Ltd (600538)?
Our model-based price target is the fair value of ¥0.5600 (as of Nov 5, 2026) from 1 valuation models. Cautious scenario ¥0.3700, optimistic scenario ¥0.7000. It is a calculation from audited fundamentals, not an analyst target.
What is the Beihai Gofar Marine Biological Industry Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.5600, about 87% lower versus a price of ¥4.17 (overvalued). Cautious scenario ¥0.3700, optimistic scenario ¥0.7000. The calculation is refreshed regularly with new filings.
What is the revenue of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
Beihai Gofar Marine Biological Industry Co Ltd reported trailing-twelve-month revenue of about 334M CNY (latest available figure, as of Nov 5, 2026).
What is the intrinsic value of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beihai Gofar Marine Biological Industry Co Ltd it is ¥0.5600 per share (as of Nov 5, 2026), against a price of ¥4.17. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Beihai Gofar Marine Biological Industry Co Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 600538 trades above its calculated fair value: price ¥4.17, fair value ¥0.5600, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600538?
No. The price is what the market pays today (¥4.17); the fair value is what the company's own numbers justify (¥0.5600). For Beihai Gofar Marine Biological Industry Co Ltd the two are ¥3.61 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beihai Gofar Marine Biological Industry Co Ltd worth?
The market values Beihai Gofar Marine Biological Industry Co Ltd at about 2.2B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥4.17; our models calculate a fair value of ¥0.5600 per share.
What do the bullish and bearish scenarios say about 600538?
Our models span a range for Beihai Gofar Marine Biological Industry Co Ltd: cautious scenario ¥0.3700, base ¥0.5600, optimistic ¥0.7000 per share (as of Nov 5, 2026, price ¥4.17). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
Balance-sheet figures for Beihai Gofar Marine Biological Industry Co Ltd (as of Nov 5, 2026): return on equity −12.5%, debt of 0.03 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 600538 from its 52-week high?
Beihai Gofar Marine Biological Industry Co Ltd trades at ¥4.17, about 44% below its 52-week high of ¥7.40 and 1% above the low of ¥4.13 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.5600 is for.
Which stocks are comparable to Beihai Gofar Marine Biological Industry Co Ltd?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, Yara International ASA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beihai Gofar Marine Biological Industry Co Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price ¥4.17, calculated fair value ¥0.5600 (−87%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600538 calculated?
We run Beihai Gofar Marine Biological Industry Co Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of ¥0.5600 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Beihai Gofar Marine Biological Industry Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
The closing price on Nov 6, 2026 was ¥4.17. Our model-based fair value is ¥0.5600, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beihai Gofar Marine Biological Industry Co Ltd right now?
The price sits above even our optimistic bull case (¥0.7000). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥0.3700 to ¥0.7000) leaves room in how you read the outcome.

Key figures of Beihai Gofar Marine Biological Industry Co Ltd

How large is the market capitalisation of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
The market capitalisation of Beihai Gofar Marine Biological Industry Co Ltd is 2.2B CNY (≈ $327M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
The price-to-sales ratio of Beihai Gofar Marine Biological Industry Co Ltd is 6.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
Earnings per share at Beihai Gofar Marine Biological Industry Co Ltd are ¥−0.1800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
The net margin of Beihai Gofar Marine Biological Industry Co Ltd is −27.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
The return on equity (ROE) of Beihai Gofar Marine Biological Industry Co Ltd is −12.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
On an EBIT basis the return on assets of Beihai Gofar Marine Biological Industry Co Ltd is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beihai Gofar Marine Biological Industry Co Ltd (600538)?
The operating margin of Beihai Gofar Marine Biological Industry Co Ltd is −3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beihai Gofar Marine Biological Industry Co Ltd (600538)?
Revenue at Beihai Gofar Marine Biological Industry Co Ltd is growing +2.4% versus a year earlier (3y avg −10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Beihai Gofar Marine Biological Industry Co Ltd (600538)?
Earnings per share at Beihai Gofar Marine Biological Industry Co Ltd are growing +12.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Beihai Gofar Marine Biological Industry Co Ltd (600538) generate?
The free cash flow of Beihai Gofar Marine Biological Industry Co Ltd is −19.9M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Beihai Gofar Marine Biological Industry Co Ltd (600538) hold?
Beihai Gofar Marine Biological Industry Co Ltd holds more cash than debt, 108M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Beihai Gofar Marine Biological Industry Co Ltd in the live analysis

One click puts Beihai Gofar Marine Biological Industry Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.